



Press release

Stockholm 14 February 2007

Affibody has obtained a granted patent on the Microbead display technology, an *in vitro* selection system

STOCKHOLM, Sweden, 14 February 2007 – Affibody AB today announced that the European patent office has granted a patent application regarding a Microbead-based system to be used for rapid selection of Affibody[®] molecules and other small binding proteins (EP1200577). Last year the US patent office granted the Company a patent on this principle (US6955877).

In contrast to selection principles based on biological systems, such as phage display, the Microbead display technology is a cell free system without the limiting factors associated with transformation of DNA into cells, enabling the creation of larger libraries. A further advantage is that all steps in the Microbead selection technology are performed *in vitro*, i.e. in the test tube, enabling automatization of all unit operations. The US and EU patents are the first to be granted on this principle and derives from the first filed patents on a bead-based selection system.

Affibody AB is focusing on developing a pipeline of molecular imaging and targeted therapeutic products based on Affibody[®] molecules. The Company believes the Microbead display technology may be applicable also for selection of other binding molecules and intends to partner the technology to bring out its full potential.

Dr. Lars Abrahmsén, Chief Scientific Officer at Affibody AB, commented: "The Company has shown that this proprietary principle works in practice, while many other groups have tried in vain to get bead-based selection to work. This is an achievement based on work by two of Affibody's founders, pioneers in this field."

Affibody AB

Ulf Boberg, Chief Executive Officer
+46 8 598 838 10
ulf.boberg@affibody.com

Erika Johnson, Chief Financial Officer
+46 8 598 838 16
erika.johnson@affibody.com

Lars Abrahmsén, Chief Scientific Officer
+46 8 598 838 12
lars.abrahmsen@affibody.com



About Affibody AB

Affibody is a biotech company that has developed a late-stage pipeline of oncology products for molecular imaging, targeted therapy and biotechnology applications. Affibody's mission is to provide the medical community with previously not available information for timely cancer diagnosis and appropriate individualized treatment regimes.

The key components of Affibody's proprietary technology platform are unique and highly specific affinity ligands: Affibody[®] molecules. These small robust protein molecules are easy to produce and can be designed to bind to any target protein. The Affibody[®] molecules are ideal for molecular imaging. Importantly, the same Affibody[®] molecule can, with a cytotoxic payload, be used for targeted therapeutics. Affibody's vision is to be a leading player in the emerging field of molecular imaging and targeted therapeutics.

The company's lead product for molecular imaging is targeting HER2, a key receptor on e.g. certain breast cancer tumors, and is expected to be commercially launched in 2009. Affibody[®] molecules specific for other oncology targets are in development and will provide a steady stream of new molecular imaging products and subsequently, targeted therapeutic products. Affibody also develops Affibody[®] molecules for various biotechnology and research applications.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute in Stockholm. Investors in Affibody AB include HealthCap, Schroder Ventures Life Sciences and Investor Growth Capital. Affibody is based in Stockholm, Sweden and has 50 employees. Further information is found on: www.affibody.com

Statements in this press release that are not strictly historical may be forward-looking and include risks and uncertainties. Therefore, though based on Affibody's current expectations, it should be duly noted that a variety of factors could cause actual results and experiences to differ materially from what is herein expressed. Risks and uncertainties include, but are not limited to, risks associated with the management of growth and international operations (including effects of currency fluctuations), variability of operating results, unforeseen changes in the diagnostic and pharmaceutical markets, market competition, rapid or unexpected changes in technologies, fluctuations in product demand, difficulties to successfully develop, adapt, produce or commercialize products, the ability to identify and develop new products and to differentiate products from those of competitors, as well as various legal hazards.